Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes

Riccardo Gliio, Enrico Balleari, Alberto Ballestrero, Anna Maria Gatti, Cristina Mareni, Giulio Massa, Franco Patrone, Mario Sessarego, Silvana Timitilli

Research output: Contribution to journalArticlepeer-review

Abstract

Recombinant human erythropoietin (rhEPO) was administered subcutane- ously to 13 anemic (Hb <10 g/dl) patients with myelodysplasia (MDS). rhEPO was given 3 times a week at doses of 75-250 U/kg body weight, over a maximum period of 24 weeks. Five patients (38%) showed a response to rhEPO treatment. rhEPO was well tolerated and without relevant side effects throughout the study. All responding patients had low but detectable pretreatment circulating erythroid progenitor cells (BFU-E) and the response to rhEPO was associated with a significant increase in BFU-E (p

Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalActa Haematologica
Volume90
Issue number2
DOIs
Publication statusPublished - 1993

Keywords

  • Anemia
  • Erythropoietin
  • Hematopoietic growth factors
  • Myelodysplastic syndromes
  • Transferrin receptor

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this